NLE Neurosensory Nursing — Seizure, Infectious, and Degenerative Neurologic DisordersStudy Notes

A seizure is a sudden, abnormal, and excessive electrical discharge of neurons in the brain, resulting in involuntary motor, sensory, or behavioral changes. Epilepsy is a chronic neurologic disorder characterized by a tendency to generate recurrent, unprovoked seizures. This distinction is critical: a single febrile seizure in a child does not constitute epilepsy, but two or more unprovoked seizures do. Seizures are classified into two major categories based on the pattern of neuronal firing: **Generalized Seizures** originate simultaneously in both cerebral hemispheres and involve loss of consciousness: - **Tonic-Clonic (Grand Mal)**: The most common type. Consists of two phases: (1) tonic phase lasting 10–20 seconds with sudden loss of consciousness, muscle stiffening, and apnea; (2) clonic phase lasting 30–40 seconds with rhythmic jerking of all extremities. Patients often experience an aura (warning sign such as a flash of light or peculiar smell) seconds before onset. Postictal confusion, drowsiness, and headache follow for 15 minutes to several hours. The patient may be incontinent. - **Absence (Petit Mal)**: Brief 5–10 second episodes of staring and unresponsiveness, often with eye fluttering. Most common in children aged 3–10 years. Can occur dozens of times daily. The patient resumes activity immediately with no postictal confusion. - **Myoclonic**: Brief, shock-like jerks of a limb or the whole body, often upon awakening. - **Atonic (Drop Attacks)**: Sudden loss of muscle tone causing the patient to fall. **Focal (Partial) Seizures** begin in a localized area of one hemisphere: - **Simple Focal**: Preserved consciousness; motor, sensory, or autonomic manifestations depending on the brain region affected (e.g., Jacksonian march with progressive spread of twitching from one finger up the arm). - **Complex Focal (Temporal Lobe)**: Loss of awareness with automatisms (lip smacking, picking at clothes, aimless wandering). Postictal confusion is common. The underlying cause determines management: idiopathic (no identifiable cause), symptomatic (secondary to a known brain lesion, infection, trauma, or metabolic disorder such as hypoglycemia), or provoked (triggered by acute illness, medication, or withdrawal).

During an acute seizure, the nurse's primary goals are to protect the airway, prevent aspiration and injury, maintain oxygenation, and time the event. These are **Maslow priority interventions** addressing physiologic safety needs. **Immediate Actions During a Seizure:** 1. **Position for airway protection**: Ease the patient to the floor or bed. Immediately turn the patient to a **lateral (side-lying) position** to prevent aspiration of secretions, saliva, or vomitus. Do NOT leave the patient supine. 2. **Protect from injury**: Gently guide limbs to prevent trauma; remove glasses, sharp objects, or jewelry from the bedside. If in a wheelchair, ease the patient to the floor. Do NOT attempt to move a seizing patient to another location. 3. **Do NOT restrain the patient**: Forceful restraint can cause muscle injuries, rhabdomyolysis, or fractures. Instead, provide a safe environment. 4. **Do NOT insert anything into the mouth**: The old practice of placing a wooden stick or airway in the mouth is contraindicated and risks aspiration, airway obstruction, broken teeth, or tongue laceration. The patient's clenched teeth will relax at the end of the seizure. 5. **Loosen tight clothing**: Unbutton or remove tight garments around the neck, chest, and abdomen to reduce airway obstruction and promote breathing. 6. **Stay with the patient**: Remain at the bedside for safety and to observe and document. 7. **Time the seizure**: Note the exact time of onset, duration of the tonic phase, duration of the clonic phase, and total duration. A seizure lasting **more than 5 minutes requires intervention**. 8. **Observe and document**: Record eye deviation, head turning, type of movements (generalized vs. focal), incontinence, tongue biting, and any injury. **Postictal Care:** 1. Keep the patient in the lateral position until fully alert. 2. Allow rest; the patient is exhausted and postictal confusion is normal. 3. Reorient the patient to person, place, and time. 4. Assess for injuries (tongue lacerations, fractured teeth, bruises). 5. Check vital signs and neurologic status. 6. Offer reassurance; the patient may be frightened or embarrassed. 7. Do not give food or drink until the gag reflex has fully returned. **Critical NLE Point**: Under RA 9173, the LRN must recognize that a seizing patient requires **immediate airway protection and lateral positioning**, not physical restraint or airway insertion. Documentation of seizure characteristics and duration guides physician decision-making regarding medication escalation.

**Status epilepticus** is defined as a state of continuous or recurring seizure activity lasting **5 minutes or more, or the recurrence of two or more seizures without regaining full consciousness between episodes**. It represents a medical and neurologic **emergency** because the combination of hypoxia, increased intracranial pressure, hyperthermia, metabolic acidosis, and hypoglycemia can result in permanent brain injury or death within minutes. **Pathophysiologic Consequences:** - **Hypoxia** from interrupted ventilation and increased cerebral metabolic demand - **Hypertension and tachycardia** followed by cardiovascular collapse - **Cerebral edema** and increased intracranial pressure (ICP) - **Hyperthermia** (temperature can exceed 40°C or 104°F) from sustained muscle activity - **Rhabdomyolysis** with myoglobinuria and acute kidney injury - **Aspiration** and pneumonia - **Sudden Unexpected Nocturnal Death in Epilepsy (SUDEP)** if not rapidly reversed **Common Precipitants:** - Abrupt withdrawal of antiseizure medications (the most common cause) - Noncompliance with medication regimen - Acute illness or infection (e.g., meningitis, encephalitis) - Metabolic disturbances (hypoglycemia, hyponatremia) - Medication interactions - Alcohol or other substance withdrawal - Acute head injury or intracranial hemorrhage - Hypoxia or respiratory failure - Severe electrolyte imbalance **Types of Status Epilepticus:** 1. **Convulsive** (generalized tonic-clonic): Visible repetitive muscle contractions; most common and obvious. 2. **Nonconvulsive** (subclinical or subtle): No or minimal visible movements but continued abnormal neuronal firing on EEG; often missed in comatose or sedated patients. Clinical signs may include automatisms, nystagmus, or unresponsiveness alone. **Immediate Management Protocol (NCM Level IV—Critical Care Nursing):** **Phase 1: Initial Stabilization (First 5–10 Minutes)** 1. **Protect airway and secure positioning**: Place patient on side; remove dentures or debris from mouth. 2. **Ensure oxygen and ventilation**: Administer **100% O₂** via non-rebreather mask; have suction and manual ventilation bag available. 3. **Establish IV access**: Obtain a **large-bore IV line** (18-gauge or larger). If peripheral IV cannot be established quickly, consider intraosseous (IO) access or give rectal benzodiazepines (if available) as an alternative. 4. **Obtain stat labs**: Blood glucose, electrolytes (Na, K, Ca, Mg), liver and kidney function, prothrombin time (PT/INR), and arterial blood gas (ABG). Fingerstick glucose must be checked immediately to rule out hypoglycemia as a reversible cause. 5. **Monitor continuously**: Attach patient to cardiac monitor, pulse oximetry, and blood pressure cuff. Insert Foley catheter to monitor urine output and detect myoglobinuria. 6. **Initiate seizure management**: - **First-line agents (0–5 minutes)**: Give **IV benzodiazepine** as rapidly as possible: - **Lorazepam (Ativan)** 4 mg IV push over 1 minute; may repeat in 5–10 minutes (total 8 mg) — preferred due to longer duration (12 hours) - **Diazepam (Valium)** 5–10 mg IV push; may repeat every 10 minutes up to 30 mg — shorter duration (30–60 minutes), risk of respiratory depression - **Monitor respiratory status closely**: Benzodiazepines suppress respirations; have intubation equipment and trained personnel ready. **Phase 2: Second-Line Therapy (If Seizures Continue After 5 Minutes)** 1. **Load with long-acting antiseizure medication** (continue benzodiazepine if possible): - **Phenytoin (Dilantin)** loading dose **15–20 mg/kg IV** at no faster than 50 mg/minute in **normal saline only** (NOT dextrose; it precipitates). Slower infusion reduces hypotension and dysrhythmia risk. Monitor cardiac rhythm continuously. - **Fosphenytoin** (Cerebyx) is a prodrug of phenytoin; can be given faster and in any IV fluid (including dextrose); **15–20 mg PE/kg (phenytoin equivalent) IV at up to 150 mg PE/min**. More expensive but safer. - **Levetiracetam (Keppra)** loading dose **20 mg/kg IV** over 15 minutes; no drug interactions, renal clearance. Increasingly favored. - **Valproic acid (Depakote)** loading dose **20–40 mg/kg IV** over 10 minutes. **Phase 3: Third-Line Therapy (Refractory Status Epilepticus—If Seizures Continue)** If seizures persist despite benzodiazepine and long-acting antiseizure medication: - **Continuous IV infusion of anesthetic agent**: - **Propofol** infusion: requires ICU setting, continuous monitoring, and mechanical ventilation - **Midazolam** infusion - **Pentobarbital** coma - These therapies require intubation, mechanical ventilation, and intensive care. **Ancillary Measures:** 1. **Treat hyperthermia**: Active cooling measures; administer acetaminophen and NSAIDs. 2. **Correct metabolic disturbances**: Administer dextrose if hypoglycemic, correct electrolyte abnormalities (especially hyponatremia and hypokalemia). 3. **Prevent complications**: Elevate head of bed 30 degrees to reduce ICP; monitor for rhabdomyolysis with urine dipstick and myoglobin levels; maintain urine output >200 mL/hour with aggressive IV hydration and possible diuretics (mannitol or furosemide) to prevent myoglobin precipitation in renal tubules. 4. **Address the underlying cause**: Treat infection, correct metabolic abnormality, manage withdrawal, or address structural lesion. 5. **Prepare for intubation and mechanical ventilation**: If seizures are not rapidly controlled, secure the airway to prevent aspiration. **Nursing Documentation and Communication:** - **Time of onset, seizure type, duration of seizure activity, response to medications, and time to seizure cessation** - **Vital signs trends, particularly temperature, BP, HR, and oxygen saturation** - **Medications given: agent, dose, time, and route** - **Patient response: seizure cessation time, level of consciousness, presence of postictal confusion** - **Complications: aspiration, injury, rhabdomyolysis signs, respiratory compromise** - **Alert hospital incident command if patient is deteriorating rapidly** **Critical NLE and RA 9173 Considerations:** Under the Nursing Practice Law, the LRN must recognize status epilepticus as a **medical emergency requiring immediate physician notification**. The nurse is responsible for rapid airway protection, obtaining IV access, administering prescribed benzodiazepines without delay, and preparing for possible intubation. Failure to escalate care or delays in medication administration are considered lapses in the standard of care.

Antiseizure medications (also called anticonvulsants) are the mainstay of epilepsy management. Selection depends on seizure type, side effect profile, comorbidities, potential drug interactions, and cost. For Philippine nursing practice, understanding the most commonly used agents and their monitoring is essential. **First-Generation (Older) Agents:** **Phenytoin (Dilantin)** - **Mechanism**: Stabilizes neuronal membrane by blocking sodium channels and enhancing gamma-aminobutyric acid (GABA). - **Indication**: Generalized tonic-clonic and focal seizures; useful for acute seizure termination and status epilepticus. - **Pharmacokinetics**: Long half-life (24–48 hours) allows once or twice daily dosing; therapeutic serum level **10–20 mcg/mL** (some sources cite 15–20); narrow therapeutic window (small difference between effective and toxic levels). - **IV Administration (Critical for NLE)**: - **Diluent**: Normal saline ONLY; precipitates in dextrose, lactated Ringer's, or acidic solutions → IV line occlusion or tissue necrosis. - **Infusion rate**: No faster than 50 mg/min IV (slower in elderly or cardiac patients to prevent dysrhythmias and hypotension). IV push can cause cardiac dysrhythmias, hypotension, syncope, and sudden cardiac death; always use controlled IV infusion pump. - **Monitoring**: Attach to cardiac monitor; have atropine and vasopressors available. Assess BP and HR before, during, and after infusion. - **IV Extravasation**: If infiltrated, tissue damage and sloughing ("purple glove syndrome") can occur; document and notify physician immediately. - **Oral Dosing**: Loading dose 1000–1500 mg (15–20 mg/kg), then maintenance 300–400 mg daily in divided doses. Administer with food to reduce GI upset (absorption is not significantly affected). - **Side Effects**: - **Chronic use**: **Gingival hyperplasia** (gum overgrowth; 50% of patients); teach meticulous oral hygiene, use a soft toothbrush, and consider dental referral for gum surgery if severe. **Hirsutism** (facial hair growth), **acne**, **coarsening of facial features** (cosmetically troublesome for some patients, especially young women). - **Neurologic**: Ataxia, vertigo, diplopia, nystagmus (dose-related; indicates toxicity if severe). - **Allergic**: Rash (mild maculopapular to severe Stevens-Johnson syndrome or toxic epidermal necrolysis [TEN]; if rash develops, stop immediately). - **Hematologic**: Megaloblastic anemia, thrombocytopenia, leukopenia (rare but serious). - **Metabolic**: Induces hepatic metabolism → increases metabolism of other drugs (oral contraceptives, warfarin, corticosteroids); contraceptive efficacy may be reduced → counsel on backup contraception. - **Folate deficiency**: Phenytoin impairs folate absorption → consider folic acid supplementation. - **Hypocalcemia and osteoporosis**: Long-term use impairs vitamin D metabolism; monitor bone density and consider vitamin D supplementation in patients on long-term therapy. - **Nursing Considerations**: - Administer IV phenytoin via a large-bore IV in normal saline with an infusion pump at no faster than 50 mg/min; monitor cardiac rhythm and vital signs continuously. - For oral therapy, advise taking with food; emphasize meticulous oral hygiene to prevent gingival hyperplasia. - Counsel women on reduced oral contraceptive efficacy; recommend backup contraception. - Never abruptly discontinue; taper over weeks to prevent seizure recurrence. - Monitor therapeutic level (goal 10–20 mcg/mL); obtain serum level 5–7 days after initiation or dose change, at steady state. - Assess for toxicity: nystagmus, diplopia, ataxia, confusion. **Carbamazepine (Tegretol)** - **Mechanism**: Sodium channel blocker; structurally related to tricyclic antidepressants. - **Indication**: Generalized tonic-clonic, focal seizures, and trigeminal neuralgia (off-label pain control). - **Pharmacokinetics**: Half-life 12–17 hours initially, then 5–20 hours (auto-induces metabolism), requiring dose adjustments. Therapeutic level 4–12 mcg/mL. - **Side Effects**: Similar to phenytoin (ataxia, diplopia); hepatic enzyme induction (reduces efficacy of other drugs); hepatotoxicity and hematologic abnormalities (agranulocytosis, aplastic anemia) — rare but serious, requiring regular CBC monitoring; hyponatremia (from SIADH); rash (including Stevens-Johnson syndrome, particularly in Asian populations with HLA-B*1502 allele — important in the Philippines; genetic screening recommended). - **Monitoring**: CBC, liver function tests (LFTs), serum sodium; baseline and periodic monitoring essential. **Valproic Acid (Depakote)** - **Mechanism**: Inhibits GABA catabolism and blocks sodium channels; broadest spectrum of all antiseizure drugs. - **Indication**: All seizure types including absence seizures; migraine prophylaxis; bipolar disorder (off-label). - **Pharmacokinetics**: Half-life 8–16 hours; therapeutic level 50–100 mcg/mL; highly protein-bound (potential drug interactions). - **Side Effects**: - **Hepatotoxicity**: Most serious; acute liver failure possible especially in infants and children. Baseline and regular LFTs mandatory. Counsel patient on signs: jaundice, vomiting, abdominal pain, dark urine. - **Hematologic**: Thrombocytopenia, pancytopenia, bleeding — requires baseline and periodic CBC. - **GI**: Nausea, diarrhea, weight gain (difficult for patients). - **Metabolic**: Hyperammonemia (can cause encephalopathy), hypoglycemia. - **Teratogenic**: Known to cause neural tube defects and developmental delays; **contraindicated or used with extreme caution in pregnant women** — consider alternative agents or add high-dose folic acid (4–5 mg daily). - **Monitoring**: LFTs (baseline, 1 month, then every 6–12 months), CBC (baseline and periodic), ammonia level if encephalopathy suspected, PT/INR if bleeding risk. - **Nursing Considerations**: Obtain baseline LFTs and CBC before starting. Administer with food to reduce GI upset. Monitor for signs of hepatotoxicity or bleeding. Counsel on medication adherence. Do NOT use in pregnant women without careful risk-benefit analysis and neurology/obstetric consultation. **Second-Generation (Newer) Agents:** **Levetiracetam (Keppra)** - **Mechanism**: Unique; does not affect GABA or sodium channels; exact mechanism not fully understood; modulates synaptic vesicle protein SV2A. - **Indication**: Adjunctive therapy for partial-onset seizures; increasingly used as first-line due to favorable side effect profile. - **Pharmacokinetics**: Half-life 6–8 hours (requires twice daily dosing), 100% renal clearance (minimal drug interactions). - **Side Effects**: Generally well-tolerated; behavioral changes (irritability, mood lability, aggression) in 10–15% especially in children; somnolence, asthenia; no significant drug interactions; minimal hepatic metabolism. - **Monitoring**: Renal function (baseline and periodic); psychiatric symptoms. - **Nursing Considerations**: Twice-daily dosing may affect compliance. Monitor for behavioral changes, especially in pediatric patients and those with psychiatric history. No hepatic monitoring needed. Safe in pregnancy (FDA category C, but generally considered safer than older agents; consult obstetrics). **Lamotrigine (Lamictal)** - **Mechanism**: Sodium channel blocker; inhibits glutamate release. - **Indication**: Partial seizures, generalized seizures, Lennox-Gastaut syndrome; also used for bipolar disorder (off-label). - **Pharmacokinetics**: Half-life 24–35 hours; significantly affected by other drugs (especially valproic acid which inhibits metabolism, requiring dose reduction). - **Side Effects**: - **Rash (Critical)**: 10–15% develop rash, and **1 in 1,000 progress to Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN)**, particularly with rapid titration, high initial doses, concomitant valproic acid use, or age <16 years. **If any rash develops, discontinue immediately and contact physician.** This is a major safety concern for NLE testing. - Other effects: Diplopia, ataxia, tremor, somnolence. - **Monitoring**: Monitor for rash; use slow titration protocols to reduce rash risk. If using with valproic acid, reduce lamotrigine dose by 50% due to enzyme inhibition. - **Nursing Considerations**: **Teach patient to report any rash immediately** — do not wait for physician appointment. Provide written instructions on rash recognition. Slow titration is essential. **Gabapentin (Neurontin)** and **Pregabalin (Lyrica)** - **Mechanism**: Modulate calcium channels; not fully understood. - **Indication**: Adjunctive therapy; neuropathic pain. - **Pharmacokinetics**: Renal clearance; minimal drug interactions. - **Side Effects**: Somnolence, ataxia, dizziness, weight gain. - **Monitoring**: Renal function. **General Nursing Principles for Antiseizure Medication Management:** 1. **Never abruptly discontinue**: Sudden withdrawal can precipitate status epilepticus or increased seizure frequency. Taper over 1–2 weeks minimum. 2. **Medication timing and compliance**: - Take medications consistently at the same time daily. - For seizure control, maintaining steady-state blood levels is critical. - Miss doses or irregular timing can reduce seizure threshold. - Counsel patients on the danger of skipping doses. 3. **Food and drug interactions**: - Some agents are affected by meal timing (e.g., phenytoin with food). - Enzyme-inducing drugs (phenytoin, carbamazepine) reduce efficacy of other medications (contraceptives, warfarin, corticosteroids). - Enzyme-inhibiting drugs (valproic acid) increase levels of other drugs. 4. **Therapeutic drug monitoring**: - Obtain baseline level before starting and again 5–7 days after initiation or dose change to reach steady state. - Therapeutic windows are specific (e.g., phenytoin 10–20 mcg/mL). - Some patients need levels above or below the therapeutic range for optimal seizure control without toxicity (individualize). - Toxicity signs: ataxia, diplopia, nystagmus, confusion, behavioral changes. 5. **Patient education**: - Explain seizure disorder and the goal of medication (prevent seizures, not cure). - Emphasize consistent daily dosing and never stopping abruptly. - Teach side effects and when to seek help (rash, signs of hepatotoxicity, behavioral changes). - Discuss driving restrictions (local laws vary; in the Philippines, patients with active seizures may not drive until seizure-free for a defined period, typically 6 months to 1 year depending on clinical circumstances). - Provide written medication information; confirm understanding. - Counsel on alcohol (lowers seizure threshold, increases side effects). - For women of childbearing age: discuss teratogenic potential and contraceptive interactions; refer to obstetrics and neurology for preconception counseling if planning pregnancy. 6. **Monitoring for complications**: - Regular lab work (LFTs, CBC) as indicated by specific drug. - Assess mental status and behavior at each visit. - Monitor for gingival hyperplasia (phenytoin), hepatotoxicity (valproic acid), rash (lamotrigine), hyponatremia (carbamazepine). 7. **Documentation**: - Record baseline labs before starting medication. - Document medication name, dose, route, frequency, and indication. - Note therapeutic level if obtained; document patient tolerance and any side effects. - Record patient education provided and patient/family understanding.

**Meningitis** and **encephalitis** are life-threatening CNS infections with high mortality if untreated. Both are medical emergencies requiring immediate diagnosis and treatment. Understanding the clinical presentation, diagnostic findings, and rapid intervention is critical for Filipino nurses working in hospitals, CHCs, and rural settings where these infections are endemic. **MENINGITIS: Inflammation of the Meninges** **Classification and Etiology:** - **Bacterial meningitis** (most life-threatening; 50% mortality if untreated): Common causative organisms: - **Neisseria meningitidis** (meningococcus): most common cause of meningitis in children and young adults; associated with epidemic spread in crowded conditions (military barracks, dormitories, CHCs in the Philippines); can progress rapidly to septic shock (Waterhouse-Friderichsen syndrome) with disseminated intravascular coagulation (DIC) and petechial/purpuric rash. - **Streptococcus pneumoniae** (pneumococcus): most common in older adults and immunocompromised; higher mortality than meningococcal; prophylaxis with pneumococcal vaccine (PCV13, PPV23) is available. - **Haemophilus influenzae type b** (Hib): less common since Hib vaccination; still seen in unvaccinated populations. - **Group B Streptococcus** (GBS): neonates and immunocompromised. - **Listeria monocytogenes**: elderly, immunocompromised, pregnant women. - **Gram-negative rods** (E. coli, Pseudomonas): hospital-acquired (nosocomial); often following head trauma, neurosurgery, or VP shunt placement. - **Viral meningitis** (aseptic meningitis; usually self-limited): Enterovirus (most common), herpes simplex virus (HSV), varicella-zoster virus, mumps (if unvaccinated), measles (if unvaccinated), HIV. - **Fungal meningitis** (usually in immunocompromised): Cryptococcus neoformans (common in HIV/AIDS in the Philippines), Histoplasma, Coccidioides. - **Tuberculous meningitis**: Mycobacterium tuberculosis; endemic in the Philippines; high morbidity and mortality; chronic presentation (weeks to months) with hydrocephalus and vasculitis. **Pathophysiology:** Infection of the meninges (dura, arachnoid, pia) causes inflammation with increased intracranial pressure (ICP), cerebral edema, impaired cerebrovascular blood flow, and vasculitis. Bacteria release inflammatory mediators (TNF, IL-1, IL-6) that increase blood-brain barrier permeability. Toxins and cell-wall components activate complement and coagulation cascades, leading to fever, altered mental status, seizures, and potentially septic shock and death. **Clinical Manifestations (Classically the Meningeal Triad):** 1. **Fever** (typically high, >38.5°C or 101.3°F; may be absent in neonates or immunocompromised) 2. **Severe headache** (often described as the worst headache of life; patient prefers dark, quiet room) 3. **Neck stiffness (Nuchal Rigidity)** (inability or pain with neck flexion; patient cannot touch chin to chest) **Additional Manifestations:** - **Altered mental status/confusion** (disorientation, lethargy, coma) — indicates higher mortality - **Seizures** (15–30% of patients, often early sign; may be generalized or focal) - **Photophobia** (light sensitivity; patient covers eyes or turns away) - **Petechial or purpuric rash** (classically seen with meningococcemia; non-blanching rash; indicates bacteremia and high mortality risk; Waterhouse-Friderichsen syndrome with fulminant meningococcemia can progress to septic shock and adrenal hemorrhage within hours) - **Nausea and vomiting** - **Joint pain (arthralgias)** and **rash** in meningococcal disease - **High fever, tachycardia, hypotension** (septic shock) **Classic Diagnostic Signs (NLE High-Yield):** **Kernig's Sign**: With the patient lying supine, flex the hip and knee to 90 degrees. Attempt to extend the knee; a positive sign is pain in the lower back or inability to straighten the leg without pain (resistance). This indicates meningeal irritation. **Brudzinski's Sign**: With the patient supine, passively flex the neck forward. A positive sign is involuntary flexion of the hips and knees (patient draws legs up). This indicates meningeal irritation. **Note**: Absence of these signs does NOT rule out meningitis, especially early in disease or in immunocompromised patients. Sensitivity of Kernig's and Brudzinski's signs is only 50% in culture-confirmed meningitis. **Diagnostic Procedures:** **Lumbar Puncture (Spinal Tap) — DEFINITIVE DIAGNOSIS:** - Obtain cerebrospinal fluid (CSF) for analysis. - **Contraindications to LP**: Papilledema, focal neurologic signs, signs of elevated ICP, or brain mass (risk of herniation). If LP is contraindicated, start empiric antibiotics based on clinical suspicion without waiting for CSF results (blood cultures are also obtained). - **CSF Analysis in Bacterial vs. Viral Meningitis**: | Finding | Bacterial | Viral | Fungal | TB | |---------|-----------|-------|--------|----| | **Appearance** | Cloudy, turbid (opaque, cannot read newsprint) | Clear (can read newsprint) | Clear to slightly turbid | Clear to slightly turbid | | **Pressure** | Elevated (>25 cm H₂O) | Normal to slightly elevated | Elevated | Elevated | | **WBC Count** | 1,000–10,000+ (neutrophil predominant, >80%) | 10–300 (lymphocyte predominant; early may be neutrophil) | 20–500 (lymphocyte predominant) | 20–500 (lymphocyte predominant) | | **Protein** | Very elevated (>200 mg/dL, often >500) | Mildly elevated (50–100 mg/dL) | Mildly to moderately elevated (50–300 mg/dL) | Moderately elevated (100–300 mg/dL) | | **Glucose** | **LOW (<40 mg/dL or CSF:blood ratio <0.4)** | **Normal (>40 mg/dL, CSF:blood ratio >0.6)** | Low to normal | **Low (<40 mg/dL)** | | **Gram Stain** | **Positive 60–80%** (diplococcus, coccobacillus, gram-negative diplococci, etc. depending on organism) | **Negative** | Negative | Negative (AFB) | | **Culture** | **Positive 80–90%** | Positive 0–5% (viral culture rarely positive) | Positive 30–40% (Cryptococcus antigen assay >80% sensitive) | Positive 50–80% (take time, weeks; culture on Löwenstein-Jensen medium) | - **Additional CSF tests**: Viral PCR (if viral meningitis suspected), bacterial antigen testing (latex agglutination or immunologic assay for Neisseria, Streptococcus, Haemophilus, GBS), Gram stain and culture, VDRL (syphilis), India ink stain (Cryptococcus), AFB stain (TB). **Blood Cultures**: Obtain before antibiotics (positive in 50–70% of bacterial meningitis cases). **Imaging**: CT or MRI if LP is contraindicated or if complications suspected (subdural empyema, ventriculitis, vasculitis). MRI may show meningeal enhancement and basilar enhancement (TB) or bilateral thalamic/hypothalamic signal abnormalities (Japanese encephalitis in the Philippines). **Management of Bacterial Meningitis (EMERGENCY PROTOCOL):** **First Priority: Start Empiric Antibiotics IMMEDIATELY (Do NOT wait for CSF results or imaging)** Delays of even 1–2 hours worsen outcomes. Antibiotics should be given before LP if LP is contraindicated or delayed. **Empiric Antibiotic Regimens (Based on Age and Risk Factors):** - **Adults and Children >3 Months**: - **Ceftriaxone** 2 g IV every 12 hours (preferred) + **Vancomycin** 15–20 mg/kg IV every 8–12 hours (covers resistant pneumococci and some gram-positive organisms). - **Alternative**: **Cefotaxime** 2 g IV every 4–6 hours (if beta-lactam allergy, use fluoroquinolone or chloramphenicol). - **Add Ampicillin** 2 g IV every 4 hours if Listeria suspected (age >50, immunocompromised, pregnancy). - **Neonates (0–3 Months)**: - **Ampicillin** 50 mg/kg IV every 12 hours + **Gentamicin** 7.5 mg/kg IV once daily (covers Listeria, GBS, gram-negatives). - Add **Cefotaxime** if bacterial meningitis confirmed. **Second Priority: Add Corticosteroids** - **Dexamethasone** 10 mg IV immediately (before or with first antibiotic dose); repeat every 6 hours for 4 days. - **Rationale**: Reduces CNS inflammation, brain edema, and ICP; improves neurologic outcomes and reduces hearing loss (major complication of meningitis). - **Timing**: Most effective if given before or within 1–2 hours of antibiotic initiation. **Third Priority: Supportive Care** - **Airway and respiratory support**: Ensure airway patency; provide O₂; prepare for intubation if altered LOC or respiratory compromise. - **ICP management**: Elevate head of bed 30 degrees; keep head in neutral position; avoid hyperthermia (treat fever with acetaminophen or NSAIDs); maintain normocapnia; ensure adequate oxygenation; minimize stimulation (quiet, dark room). Monitor for signs of ICP elevation (decreased LOC, pupil changes, focal motor deficits, Cushing's triad: bradycardia, hypertension, irregular respirations). - **Fluid and electrolyte management**: Start IV fluids (typically normal saline); avoid fluid overload (risk of cerebral edema). Monitor for hyponatremia (SIADH is common). Foley catheter for accurate urine output. - **Seizure precautions**: Have suction, emergency drugs, and airway equipment available. Seizures occur in 15–30%; treat with antiseizure medications if seizures occur. - **Temperature control**: Treat hyperthermia with antipyretics and cool measures (cooling blanket if needed); fever increases metabolic demand and ICP. - **Nutrition and hydration**: IV fluids initially; advance to oral or nasogastric feeding once safe to eat/drink. Monitor fluid balance. - **Monitoring**: Continuous vital sign and neuro monitoring; serial neurologic exams at least every 1–2 hours initially; CT or MRI if neurologic deterioration occurs (evaluate for complications: subdural empyema, ventriculitis, hydrocephalus, vasculitis). **Infection Control: DROPLET PRECAUTIONS** - **Duration**: For the first 24 hours after initiation of effective antibiotics. - **Indications**: - Suspected or confirmed **Neisseria meningitidis** - Suspected or confirmed **Haemophilus influenzae** (unvaccinated) - Suspected meningitis (until bacterial cause is ruled out or organism is identified and respiratory isolation is no longer indicated) - **Precautions**: Mask for patient and all persons entering room; restrict patient movement outside room; cohort infected patients if necessary. - **Post-Exposure Prophylaxis for Close Contacts** (esp. Philippines with limited vaccine availability): - **Neisseria meningitidis contacts**: **Rifampin** 600 mg orally every 12 hours for 2 days (or single IM ceftriaxone 250 mg, or oral fluoroquinolone such as ciprofloxacin 500 mg single dose). Give within 24 hours of patient diagnosis; most effective if started within 14 days. - **Haemophilus influenzae type b contacts** (unvaccinated): **Rifampin** 20 mg/kg once daily for 4 days (max 600 mg/dose). - **Streptococcus pneumoniae**: No routine prophylaxis; consider vaccination for unvaccinated contacts. **Management of Viral Meningitis:** - Supportive care: Rest, analgesics, antipyretics. - If **herpes simplex meningitis** suspected based on elevated protein and lymphocytic CSF, consider **IV acyclovir** (though benefit is debated if HSV PCR is negative on CSF). - Most cases self-resolve within 1–2 weeks. - Reassure patient of good prognosis compared to bacterial meningitis. **Complications of Meningitis:** - **Hearing loss** (sensorineural): 25–30% of survivors, especially with pneumococcal or meningococcal disease; audiology assessment post-recovery is recommended. - **Subdural empyema or abscess**: Collection of pus between dura and brain; presents with neurologic deterioration; requires imaging and drainage. - **Ventriculitis**: Infection of ventricular system; poor prognosis. - **Hydrocephalus**: Obstruction of CSF flow; may require ventriculoperitoneal (VP) shunt. - **Vasculitis**: Inflammation of cerebral blood vessels; can cause stroke. - **Seizures**: During acute infection or later (post-meningitis seizure disorder in 5–10%). - **Cognitive impairment**: Subtle deficits in memory, attention, executive function in 10–20% of survivors. - **Waterhouse-Friderichsen syndrome** (fulminant meningococcemia): Massive adrenal hemorrhage, DIC, shock, multi-organ failure, death; can occur within hours of onset. **Prevention:** - **Vaccination**: Meningococcal conjugate vaccines (MCV4, MenB), pneumococcal conjugate vaccine (PCV13) and polysaccharide vaccine (PPV23), Hib vaccine (included in routine Philippine EPI schedule). - **Public health measures**: Clean water, sanitation, healthcare worker infection control. --- **ENCEPHALITIS: Inflammation of Brain Tissue** **Etiology:** - **Viral encephalitis** (most common, 90% of cases): - **Herpes simplex virus (HSV-1 and HSV-2)**: Most common sporadic cause in developed countries; high mortality (40%) if untreated; responds to IV acyclovir. - **Arboviruses** (arthropod-borne): Transmitted by mosquitoes and ticks; - **Japanese encephalitis (JE)**: Most common cause of viral encephalitis in Asia, including the Philippines; endemic in tropical and subtropical regions; seasonal transmission (rainy season); high mortality (20–30%) and high morbidity (30% of survivors have neurologic sequelae); preventable by JE vaccine (included in Philippine EPI schedule or available for travelers). - **Dengue**: Dengue virus with neurologic involvement; dengue-associated encephalitis rare but possible. - **West Nile virus**, **Zika virus**: Emerging threats. - **Enteroviruses**, **paramyxoviruses** (mumps if unvaccinated, measles if unvaccinated), **varicella-zoster virus**. - **HIV**: Acute HIV meningoencephalitis; chronic HIV encephalopathy (AIDS dementia complex) if CD4 <50 cells/μL. - **Bacterial encephalitis** (rare; usually with meningitis): Abscesses, ventriculitis. - **Fungal encephalitis** (immunocompromised): Cryptococcus, Histoplasma, Coccidioides. - **Parasitic**: Cysticercosis (Taenia solium; endemic in Philippines), malaria (cerebral malaria). **Pathophysiology:** Viral infection of brain parenchyma causes inflammation, neuronal damage, and cerebral edema. Arboviruses show predilection for deep brain structures (basal ganglia, thalamus, midbrain, spinal cord), particularly in Japanese encephalitis. **Clinical Manifestations:** - **Fever**, **headache** (like meningitis). - **Altered mental status** (more prominent than in meningitis): confusion, disorientation, hallucinations, delirium, coma. - **Seizures** (more common than in meningitis; 30–50% of cases). - **Focal neurologic deficits** (indicating brain tissue damage): - **Motor weakness** or **paralysis** (mono-, hemi-, or tetraplegia depending on extent and location of involvement). - **Cranial nerve palsies** (III, IV, VI, VII commonly affected; III nerve palsy presenting with ptosis and dilated pupil is concerning for brainstem involvement or increased ICP). - **Aphasia** or **dysarthria** (if language areas affected). - **Ataxia** or **tremor** (if cerebellum or basal ganglia affected). - **Behavioral changes**, **personality changes**. - **Stiff neck** (less common than meningitis; 25% of viral encephalitis cases). - **Rash** (if measles, dengue, or other exanthematous virus). **Japanese Encephalitis (JE) — Philippine Public Health Concern:** - **Epidemiology**: Endemic in Philippines; peak transmission August–November (rainy season); affects rural and urban areas; highest incidence in children and elderly; sporadic cases and outbreaks occur. - **Transmission**: Culex mosquito bites; amplification in pigs and birds. - **Clinical**: Abrupt fever, headache, confusion; **distinctive neuro pattern**: MRI shows bilateral thalamic, basal ganglia, midbrain, and brainstem involvement. **Extrapyramidal signs** (rigidity, tremor, dystonia) are characteristic. Seizures common. High mortality (20–30%) and high morbidity (30% of survivors have permanent sequelae: chronic seizures, parkinsonism, cognitive impairment, speech disorders). - **Diagnosis**: CSF PCR (most sensitive), IgM ELISA on CSF/serum, viral culture. - **Treatment**: Supportive care; no specific antiviral. Supportive care includes seizure management, ICP control, respiratory support. - **Prevention**: **JE vaccine** (formalin-inactivated or live attenuated, depending on formulation) — effective 80–95%; included in Philippine EPI schedule for all children; also available for travelers and high-risk groups. Vector control (insecticide-treated nets, environmental management to reduce mosquito breeding sites). **Diagnostic Procedures for Encephalitis:** **CSF Analysis:** - **Appearance**: Clear (usually). - **Pressure**: Normal to elevated. - **WBC Count**: 10–300 (lymphocyte predominant, but early may show neutrophil predominance). - **Protein**: Mildly to moderately elevated (50–200 mg/dL). - **Glucose**: **Normal (unlike meningitis where it's low)**; CSF:blood glucose ratio >0.6. - **Gram stain and culture**: Negative (rules out bacterial). - **Viral PCR**: **Most specific and sensitive for HSV, enterovirus, arboviruses** (positive in 50–80% of cases); test for HSV, EV, arboviruses based on clinical suspicion and local epidemiology. - **IgM/IgG serology**: For arboviruses (JE, dengue); IgM indicates acute infection. **Blood Culture and Serology**: Viral serology to confirm diagnosis if CSF PCR negative or to detect arboviruses. **Imaging**: - **MRI** (preferred over CT): - **HSV encephalitis**: Typically temporal lobe signal abnormalities (T2/FLAIR hyperintensities), often unilateral. - **Japanese encephalitis**: Bilateral thalamic, basal ganglia, midbrain, brainstem signal abnormalities (characteristic pattern in Philippines). - **Other findings**: Gray matter involvement, hydrocephalus, cerebral edema. - **CT**: Assess for cerebral edema, mass effect, signs of increased ICP. **EEG**: May show nonspecific slowing or focal abnormalities; in HSV encephalitis, periodic sharp wave complexes (PSWCs) every 2–3 seconds over temporal regions are characteristic (though not pathognomonic). **Management of Viral Encephalitis:** **First Priority: Empiric Treatment for Herpes Simplex Encephalitis (Do NOT Wait for Confirmation)** - **IV Acyclovir** 10 mg/kg IV every 8 hours (or 30 mg/kg/day divided into 3 doses) for 10–14 days. - **Rationale**: HSV encephalitis is a medical emergency with 40% mortality if untreated; acyclovir dramatically improves outcomes even if HSV is later ruled out. Start based on clinical suspicion and CSF findings (lymphocytic CSF with normal glucose, temporal lobe imaging findings). **Supportive Care (Similar to Meningitis):** - **Airway and respiratory support**. - **ICP management**: Elevate head 30 degrees, maintain normothermia, optimize oxygenation and ventilation, minimize stimulation. - **Seizure management**: Antiseizure medications for seizures or seizure prophylaxis in high-risk cases (acyclovir can cause EEG abnormalities and seizures). - **Fluid and electrolyte balance**: Monitor for SIADH and hyponatremia. - **Nutrition and hydration**: IV fluids; nasogastric feeding if needed. - **Monitoring**: Continuous vital signs, serial neuro exams, repeat imaging if clinical deterioration. **Vector Control and Prevention (For Arboviral Encephalitis in Philippines):** - **Insecticide-treated bed nets**: Especially during rainy season when mosquito activity peaks. - **Environmental management**: Eliminate standing water (Culex mosquito breeding sites); drainage of swamps; larvicide application. - **Vaccination**: Japanese encephalitis vaccine for at-risk populations (children, rural residents, elderly, healthcare workers in endemic areas). - **Personal protection**: Wear long sleeves, long pants, insect repellent (DEET) during dawn and dusk when Culex mosquitoes are active. **Complications of Encephalitis:** - **Status epilepticus**. - **Cerebral edema and increased ICP**: May require osmotic therapy (mannitol), sedation, mechanical ventilation, possible decompressive craniectomy in severe cases. - **Neurologic sequelae**: Chronic seizures, cognitive impairment, behavioral changes, movement disorders (Parkinson-like), coma, death. - **Secondary infection**: Aspiration pneumonia, urinary tract infection. **Prognosis:** - **HSV encephalitis**: With IV acyclovir, mortality 10–20%; neurologic morbidity 30–50%. - **Japanese encephalitis**: Mortality 20–30% (higher in elderly); significant morbidity in survivors (30%). - **Arboviral encephalitis in general**: Depends on virus; prognosis often poor. **Nursing Implications:** - Early recognition of meningitis and encephalitis and rapid escalation of care are critical. - Under RA 9173, the LRN must implement droplet precautions for suspected bacterial meningitis, provide IV antibiotics immediately, monitor neurologic status closely, manage ICP elevation, prevent complications (aspiration, seizures, nosocomial infection), and support family education and psychosocial needs. - In the Philippine setting with dengue, Japanese encephalitis, and TB meningitis endemic, nurses must be alert to arboviral and TB CNS infection presentations. - Public health nursing roles include vaccination support (EPI programs), vector control education, and health promotion in endemic regions.

**Parkinson's disease (PD)** is a progressive, chronic neurodegenerative disorder characterized by **loss of dopamine-producing neurons in the substantia nigra pars compacta** of the basal ganglia. This dopamine deficiency creates an imbalance between dopamine and acetylcholine in the basal ganglia, resulting in the cardinal motor signs and a constellation of nonmotor symptoms that significantly impact quality of life. **Epidemiology:** - **Incidence**: Increases with age; most common in individuals >60 years old; prevalence ~1–2 per 1,000 persons in developed countries. - **Etiology**: Idiopathic (90% of cases); some cases familial (PARK genes) or secondary to toxins (MPTP), medications (antipsychotics, antiemetics), or head trauma. - **In the Philippines**: Growing prevalence as population ages; access to dopaminergic medications may be limited in rural areas; neurology specialist care concentrated in urban centers. **Pathophysiology:** Neuronal degeneration in the substantia nigra leads to dopamine depletion in the striatum (caudate and putamen). The basal ganglia normally maintain a balance between dopaminergic (inhibitory) and cholinergic (excitatory) neurotransmission. Loss of dopamine results in **relative acetylcholine excess**, which disrupts normal motor control, leading to: - **Hypokinetic movement disorder** (poverty of movement): bradykinesia, rigidity, postural instability. - **Tremor**: Due to abnormal oscillatory activity in basal ganglia circuits. - **Dysregulation of motor planning and execution**. **Clinical Manifestations (The Tetrad + More):** **The Classic Triad (Patients May Not Have All Three):** 1. **Tremor** ("pill-rolling" tremor): - **Resting tremor**: Most characteristic; present when limb is at rest and supported against gravity; decreases or disappears with intentional movement (flexion-extension of thumb and fingers resembles rolling a pill between fingers). - **Frequency**: 4–6 Hz. - Typically begins unilaterally (one hand) and may progress to bilateral over years. - Absent in 25% of patients (akinetic-rigid subtype). - Emotional stress, anxiety, fatigue exacerbate the tremor. 2. **Rigidity** ("Cogwheel Rigidity"): - **Increased muscle tone** throughout the range of passive movement; felt as uniform resistance or "lead pipe" rigidity. - **Cogwheel rigidity**: Ratchety, interrupted resistance due to superimposed tremor; particularly characteristic of PD. - **Testing**: Flex and extend patient's arm slowly; assess for uniform resistance. Have patient perform ballistic movements with contralateral arm to distract attention (Froment maneuver), which may unmask mild rigidity. - More prominent in proximal muscles. 3. **Bradykinesia** (Slow Movement / Hypokinesia): - **Poverty and slowness of movement**; progressive slowing with repetitive movements (decrement). - Manifests as slow handwriting (micrographia), slow foot tapping, slow speech, slow facial movements. - Often the most disabling symptom as disease progresses. - Assessed with rapid finger tapping, foot tapping, or hand pronation-supination; normal rate is 6–8 taps per second; PD patients typically achieve <5 taps/second with progressive slowing. **Fourth Sign: Postural Instability** - Loss of postural reflexes; impaired ability to maintain balance when pushed or when environment shifts. - Risk of falls increases significantly. - Often develops later in disease course. - **Pull test**: Examiner stands behind patient and gently pulls backward at shoulders; normal response is 1–2 corrective steps; PD patients may stagger or fall (positive pull test). **Additional Motor Signs:** **Gait Disturbance:** - **Shuffling gait**: Short, rapid steps with reduced arm swing (arms may not swing on one side initially). - **Festination**: Gait acceleration; patient's pace quickens involuntarily, sometimes culminating in a run ("festinating to a wall"). - **Freezing of gait (FOG)**: Sudden inability to initiate or continue walking despite wanting to move; often triggered by narrow spaces, doorways, or changes in environment; improves with visual cues (walking over lines or with music). **Facial Changes:** - **Mask-like face** (hypomimia): Reduced facial expression due to rigidity of facial muscles; patient appears blank or sad despite normal mood. - Reduced blink rate (normal 15–20 blinks/min; PD patients blink 3–5 times/min). **Micrographia:** - Handwriting becomes progressively **smaller and more cramped** with writing fatigue; signature loses size consistency. - **Diagnostic sign**: Asking patient to write "PARKINSONS" or to copy a phrase; letters become progressively smaller (unlike normal writing). **Stooped Posture:** - Progressive forward flexion of the trunk; loss of lumbar lordosis. - Increases risk of falls and reduces respiratory capacity. **Speech and Swallowing:** - **Hypokinetic dysarthria**: Quiet, monotone ("mumbling"), rapid speech (tachyphemia). - **Dysphagia**: Weak pharyngeal and esophageal contractions increase aspiration risk; weight loss common. **Nonmotor Symptoms (Often Underrecognized but Highly Impactful):** - **Autonomic dysfunction**: Orthostatic hypotension (especially in advanced disease or with dopamine agonists), urinary dysfunction (urgency, nocturia, incontinence), erectile dysfunction, constipation (very common, affects 60–80%). - **Cognitive and psychiatric**: Depression (50%), anxiety, apathy (akinetic mutism), mild cognitive impairment (MCI), and eventual dementia in 24–31% of patients after 10 years (Parkinson's disease dementia, PDD). - **Sleep disturbances**: Insomnia, REM sleep behavior disorder (acting out dreams, potentially dangerous), excessive daytime somnolence (especially with dopamine agonists). - **Sensory**: Olfactory dysfunction (reduced sense of smell, often precedes motor symptoms by years), pain and dysesthesias. - **Psychotic symptoms**: Hallucinations (usually visual, benign; patient sees people or animals that aren't there but recognizes them as not real initially), paranoid delusions (often related to medication or disease progression). **Stages of Parkinson's Disease (Hoehn and Yahr Scale):** - **Stage 1**: Unilateral involvement; minimal functional impairment. - **Stage 2**: Bilateral involvement; still relatively independent; balance/postural reflexes intact. - **Stage 3**: Mild postural instability; functional impairment; slower movement but still independent. - **Stage 4**: Severe functional impairment; falls risk high; assistance with ADLs. - **Stage 5**: Severe disability; confined to bed or wheelchair; full care dependence. **Diagnosis:** Clinical diagnosis based on **cardinal motor signs**, **asymmetric onset** (typically unilateral initially), **response to dopaminergic therapy** (gold standard: marked improvement with levodopa), and **gradual disease progression**. No specific lab test or imaging confirms PD (diagnosis is clinical). **SPECT imaging** (dopamine transporter scan) shows reduced striatal uptake, supporting diagnosis if clinical picture is unclear. **MRI** rules out atypical parkinsonian syndromes (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration) or secondary causes (stroke, tumor, normal pressure hydrocephalus). **Red Flags for Atypical Parkinsonism (Not Pure PD):** - Prominent early postural instability with falls (multiple system atrophy, PSP, CBD). - Prominent early cognitive decline or dementia (Lewy body dementia, CBD). - Vertical gaze palsy or downward gaze difficulty (PSP). - Asymmetric cortical signs (CBD). - Rapid progression (<3 years from onset to disability). - Lack of response to levodopa. - Early autonomic dysfunction with syncope or urinary retention (multiple system atrophy). --- **PHARMACOLOGIC MANAGEMENT:** **Treatment Goals:** 1. Maximize motor control and maintain independence. 2. Minimize medication side effects. 3. Preserve and extend medication efficacy (goal is to delay need for higher doses or additional agents). 4. Manage nonmotor symptoms. 5. Provide psychosocial support and quality of life. **Principles:** - **Start low, go slow**: Dopaminergic medications are typically started at low doses and increased gradually based on clinical response and tolerability. - **Timing is critical**: Doses should be taken consistently at the same time daily to maintain steady-state brain dopamine levels. - **Avoid prolonged off periods**: As disease advances, patients develop "on-off" fluctuations (alternating periods of good medication response and poor response); maintaining smooth dopaminergic stimulation is important. - **Medication burden**: Early disease may be managed with a single agent; later disease requires multiple agents with increased side effects. **First-Line Dopaminergic Agents:** **Levodopa-Carbidopa (L-DOPA-Carbidopa / Sinemet)** - **Gold Standard**: Most effective dopaminergic agent; provides the most robust motor improvement. - **Mechanism**: Levodopa (L-dihydroxyphenylalanine) crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a peripheral decarboxylase inhibitor (does not cross the blood-brain barrier) that prevents premature conversion of levodopa to dopamine in the periphery, reducing GI side effects and ensuring more levodopa reaches the brain. - **Pharmacokinetics**: Short half-life (~60–90 min); requires dosing 3–4 times daily. Absorbed in small intestine; high-protein meals compete for absorption → take on empty stomach (½–1 hour before meals) or with low-protein meal; separate high-protein meals from medication times by 1–2 hours. - **Dosing**: Start low (carbidopa-levodopa 25/100 mg once or twice daily) and titrate based on response. Typical maintenance: 200–800 mg/day of levodopa divided into 3–4 doses. - **Side Effects**: - **Short-term (Early in Treatment)**: - **Nausea and vomiting** (mediated by dopamine agonism in chemoreceptor trigger zone); mitigated by taking with food (though absorption reduced) or adding domperidone (peripheral dopamine antagonist that does not cross blood-brain barrier; available in Philippines; preferred over metoclopramide which blocks brain dopamine receptors). - **Orthostatic hypotension**: Transient drop in BP when standing; counsel on rising slowly, hydration, compression stockings if needed. - **Dizziness, headache, nervousness**. - **Long-Term (Chronic Use — Years to Decades)**: - **Motor Complications (Most Concerning)**: - **"On-Off" Phenomenon**: Unpredictable transitions between periods of good medication response ("on" states) and poor response ("off" states); duration and occurrence become less predictable over time. Patient may switch abruptly from good mobility to freezing and rigidity. - **"Wearing-Off" Effect**: Gradual decline in duration of medication benefit as doses are missed or disease progresses; may require more frequent dosing (e.g., from 4x daily to 5–6x daily). The Wearing-Off phenomenon often precedes On-Off phenomenon. - **Dyskinesias (Involuntary Movements)**: **Peak-dose dyskinesias** (occur when levodopa levels are highest; chorea, athetosis, ballism), **diphasic dyskinesias** (occur as levels rise and fall; early morning dystonia), **off-period dystonia** (sustained muscle contractions during off periods, esp. early morning). Can involve face, limbs, trunk, and neck; severely disabling if severe. Occur in 40% of patients after 5–6 years of levodopa therapy. - **Motor Freezing**: Sudden inability to move despite wanting to; not responsive to normal movement strategies but may respond to visual or auditory cues (stepping over lines, music, metronome). - **Psychiatric Complications**: - **Levodopa-Induced Psychosis (LIP)**: Hallucinations (usually visual and benign initially), paranoid delusions, agitation. Occurs in advanced disease, especially in elderly or cognitively impaired; triggered by high levodopa doses. Managed by reducing levodopa dose and adding atypical antipsychotic (quetiapine) that does not worsen parkinsonism. - **Impulse Control Disorder (ICD)**: Pathologic gambling, hypersexuality, compulsive shopping, binge eating; more common with dopamine agonists than levodopa; risk increases with higher doses and younger onset age. - **Dysphonia and Dysphagia**: Worsening with disease; aspiration risk increases. - **Cognitive Decline**: From PD itself (not primarily medication); dementia in ~25% by 10 years. - **Contraindications**: Narrow-angle glaucoma, pheochromocytoma, concurrent use of MAOIs (risk of hypertensive crisis) — though some newer selective MAO-B inhibitors are safe with levodopa. - **Drug Interactions**: High-protein meals reduce absorption; some antipsychotics (especially first-generation) worsen parkinsonism; SSRIs generally safe (though sertraline best tolerated). **Clinical Pearls for Levodopa-Carbidopa Use:** - Patient education is critical: take doses on time, maintain consistent dosing intervals, separate from high-protein meals, and never abruptly stop (risk of neuroleptic malignant syndrome-like state). - Monitor for motor complications; document on-off patterns, dyskinesias, freezing episodes. - As disease advances, shorter duration of benefit and increased dyskinesias necessitate dose adjustments, more frequent dosing, or addition of adjunctive agents. - Extended-release formulations (carbidopa-levodopa CR) or newer depot formulations aim to smooth dopaminergic stimulation and reduce dyskinesias, but efficacy is variable and absorption unpredictable. **Dopamine Agonists (Adjunctive Agents)** - **Examples**: Pramipexole (Mirapex), ropinirole (Requip), bromocriptine (less used now), rotigotine patch. - **Mechanism**: Directly stimulate dopamine receptors (D1, D2, D3) in the brain. - **Use**: Added to levodopa in later disease to reduce levodopa dose and motor complications; can also be monotherapy in early disease (though less effective than levodopa; benefits often transient). - **Side Effects**: **Somnolence (sudden sleep attacks)** — patient may fall asleep while driving or performing activities; requires counseling on driving safety. **Orthostatic hypotension**, **peripheral edema**, **hallucinations** (especially with higher doses or in elderly), **impulse control disorders** (gambling, hypersexuality, compulsive shopping; more common than with levodopa; monitor and counsel patients). - **Monitoring**: Assess for excessive daytime somnolence; use Epworth Sleepiness Scale if high risk. Counsel on driving safety and need to disclose somnolence to licensing authorities (in Philippines, driving restrictions depend on clinical judgment and local regulations). **MAO-B Inhibitors (Adjunctive)** - **Examples**: Selegiline (deprenyl), rasagiline. - **Mechanism**: Selectively inhibit monoamine oxidase-B (enzyme that breaks down dopamine in the brain); prolong levodopa effect. - **Use**: Added to levodopa to extend medication duration and reduce "wearing-off"; modestly slow progression early in disease (controversial; conflicting data). - **Side Effects**: Minimal at recommended doses (selectivity for MAO-B is lost at higher doses, risking hypertensive crisis if combined with tyramine-rich foods or other sympathomimetics). **Insomnia, nervousness** if given late in day. - **Dosing**: Selegiline 5 mg in morning; rasagiline 1 mg daily. - **Advantages**: Safe, minimal side effects, well-tolerated long-term. **COMT Inhibitors (Adjunctive)** - **Examples**: Entacapone (Comtan), levodopa-carbidopa-entacapone (Stalevo). - **Mechanism**: Inhibit catechol-O-methyltransferase (COMT), an enzyme that metabolizes dopamine peripherally and in the brain; prolong levodopa effect and smooth dopaminergic stimulation. - **Use**: Added to levodopa in patients with wearing-off or off periods; reduces fluctuations and dyskinesias. - **Side Effects**: **Diarrhea** (20–30% of patients; can be severe), **urine discoloration** (yellow-brown; cosmetic but concerning if not warned), **increased dyskinesias** (due to higher dopamine levels), **hepatotoxicity** (rare but monitor LFTs at baseline and periodically). - **Dosing**: Entacapone 200 mg with each dose of levodopa (max 800 mg/day). Stalevo combines carbidopa-levodopa-entacapone in one tablet for convenience. **Anticholinergic Agents (Now Rarely Used)** - **Examples**: Benztropine (Cogentin), trihexyphenidyl. - **Mechanism**: Block central acetylcholine receptors; compensate for dopamine-acetylcholine imbalance in early disease. - **Side Effects**: **Cognitive impairment, confusion, memory loss** (especially in elderly or at-risk for dementia; contraindicated in PD dementia), **urinary retention, constipation, dry mouth, narrow-angle glaucoma risk, hallucinations**. - **Decline in Use**: As newer agents became available, anticholinergics fell out of favor due to cognitive risks; now used rarely and cautiously (mainly for tremor-dominant early-stage PD in younger patients without cognitive risk). **Emerging and Adjunctive Agents:** - **Adenosine A2A Receptor Antagonist (Istradefylline)**: Prolongs levodopa effect; used in off-period fluctuations. - **Amantadine**: Nonselective NMDA antagonist; weak dopamine agonist; used for dyskinesias and off-period freezing. **Surgical Interventions:** - **Deep Brain Stimulation (DBS)**: Neurosurgical placement of programmable electrodes in the subthalamic nucleus (STN), globus pallidus interna (GPi), or ventral intermediate thalamus (VIM). Indicated in advanced disease (5+ years duration, motor complications despite optimized medical therapy) with good prior response to levodopa. Benefits: reduced medication requirements, improved dyskinesias, improved motor fluctuations. Drawbacks: surgical risks, device malfunction, need for ongoing programming and follow-up. - **Thalamotomy**: Thermal ablation or radiosurgery; less commonly used; mainly for tremor when DBS contraindicated. - **Limitations in Philippines**: DBS is expensive and available only in major tertiary centers; not accessible to most patients due to cost. **Nondopaminergic Management of Nonmotor Symptoms:** - **Depression**: SSRIs (sertraline preferred; tricyclic amitriptyline also used). - **Anxiety**: SSRIs, buspirone, or benzodiazepines (short-term use only due to dependence risk and cognitive effects). - **Constipation** (very common): Stool softeners, high fiber, adequate hydration, increased physical activity; osmotic laxatives (polyethylene glycol); last-resort: TriLone enemas. - **Orthostatic hypotension**: Fluid and salt intake (2–3L fluids, 6g salt daily), compression stockings, sleeping with head elevated, midodrine (sympathomimetic), fludrocortisone (mineralocorticoid). - **Urinary urgency/incontinence**: Pelvic floor exercises, anticholinergics (tolterodine), oxybutynin (but watch cognitive effects). - **Erectile dysfunction**: Phosphodiesterase-5 inhibitors (sildenafil); counseling. - **Sleep disorders**: Sleep hygiene, melatonin, sedating antidepressants (mirtazapine), dopamine agonists if REM sleep behavior disorder; avoid benzodiazepines (dependence, cognitive effects). --- **NURSING MANAGEMENT AND CARE PLANNING:** **Priority Nursing Diagnoses (NANDA):** 1. **Impaired physical mobility** related to bradykinesia, rigidity, postural instability, and motor complications (dyskinesias, freezing). 2. **Risk for falls** related to postural instability, gait disturbance, orthostatic hypotension. 3. **Imbalanced nutrition: less than body requirements** related to dysphagia, slow eating, reduced appetite, depression. 4. **Ineffective airway clearance** related to dysphagia and aspiration risk. 5. **Constipation** related to hypokinesia, medication effects, reduced activity. 6. **Social isolation** related to functional limitations, depression, difficulty with communication. 7. **Deficient knowledge** regarding disease process, medication management, safety measures. 8. **Risk for medication non-adherence** related to complex dosing schedule, side effects, cost (in Philippine setting). **Interventions and Patient Education:** **Medication Management and Adherence:** - Emphasize the importance of consistent, on-time dosing to maintain steady dopamine levels and prevent medication wearing-off. - Teach the relationship between levodopa doses and meals: take on empty stomach (½–1 hour before or 1–2 hours after eating) to maximize absorption; separate high-protein meals from medication by at least 1–2 hours. - Provide written schedule; use pill organizer if helpful; consider alarm reminders on phone. - Counsel on never abruptly stopping medications (risk of severe deterioration, neuroleptic malignant syndrome-like state, status epilepticus if also on antiseizure drugs). - If doses are missed, take next dose at regular time (do not double-dose). - Report side effects (nausea, orthostatic hypotension, dyskinesias, hallucinations, impulse control symptoms) promptly; dose adjustment or additional agent may be needed. - Cost considerations in Philippines: Dopaminergic medications can be expensive; explore insurance coverage, government assistance programs, or generic options; discuss with physician and patient regarding treatment goals and affordability. **Fall Prevention and Safety:** - **Environmental modification**: Remove clutter, ensure adequate lighting, install grab bars and handrails in bathrooms and along stairs, use nonslip footwear, consider bed alarm if falls at night. - **Gait and balance training**: Supervised physical therapy focusing on balance exercises, strengthening, gait training with visual/auditory cues (music, stepping over lines). - **Freezing management**: Teach patient and caregiver strategies for breaking freezing episodes: visual cues (stepping over imaginary lines marked on floor), auditory cues (count or use metronome), verbal cueing from caregiver ("step, step, step"), sitting and standing, sidestepping. - **Orthostatic hypotension**: Rise slowly from sitting or lying; dangle legs before standing; sit to stand from firm chair; avoid hot showers; increase hydration and dietary salt; compression stockings; floor exercises before getting out of bed. - **Fall documentation**: Record falls (when, where, how), injuries, and clinical context (medication timing, off-period, dyskinesia); trends guide treatment adjustments. **Nutrition and Swallowing:** - **Dysphagia screening**: Assess for difficulty swallowing, coughing or choking with meals, wet voice quality, drooling, weight loss. If dysphagia suspected, speech-language pathology referral for formal swallowing assessment. - **Swallowing precautions**: - Sit upright during eating and remain upright for 30 minutes after eating. - Eat slowly; take small bites; chew well before swallowing. - Alternate solid and liquid swallows to clear bolus. - Thick liquids (nectar or honey consistency) are often safer than thin liquids (thin liquids are aspirated more easily due to reduced pharyngeal control). - Avoid hard, sticky, dry, and crumbly foods. - If NPO (nothing by mouth) due to severe dysphagia, consider feeding tube (nasogastric or PEG) and refer for swallowing therapy. - **Nutrition**: - Ensure adequate nutrition; weight loss is common and contributes to weakness and falls. - Offer small, frequent meals (6–8 per day) rather than 3 large meals; nutrient-dense foods (eggs, cheese, yogurt, fortified beverages). - Fiber intake to prevent constipation (but monitor swallowing if high-fiber foods difficult to manage). - Encourage fluid intake (2–3L daily unless fluid-restricted); adequate hydration reduces constipation and orthostatic hypotension. - Anticipate medication timing: larger meals after medications for medication absorption considerations. **Bowel Management:** - Constipation is very common and affects quality of life; proactive approach essential. - **Prevention**: Adequate hydration (2–3L daily), dietary fiber (fruits, vegetables, whole grains, or psyllium supplement), physical activity as tolerated, regular toilet routine (establish bathroom schedule, allow adequate time). - **Treatment**: Start with dietary measures; if inadequate, add stool softener (docusate 100–200 mg daily), osmotic laxative (polyethylene glycol 1 teaspoon to 1 tablespoon daily in water, gradually increased to effect), or bisacodyl suppository for scheduled bowel movements. - **Bowel program**: Establish regular time (e.g., after breakfast) for bowel movement attempt; use bathroom immediately after stimulation (warm drink, physical activity). - **Avoid long-term laxative dependence**: Continual use can lead to dependence and electrolyte abnormalities; maintain preventive measures. **Mobility and Exercise:** - **Physical therapy and occupational therapy**: Beneficial for gait training, balance exercises, strength training, and ADL adaptation. - **Encourage regular exercise**: Aerobic activity (walking, swimming, cycling) and resistance training improve motor symptoms, mood, and constipation. Target 30 minutes moderate activity most days weekly if tolerated. - **Occupational therapy**: Adaptation of ADLs (dressing, grooming, eating); large-grip utensils and adaptive equipment; home modification. - **Assistive devices**: Walker or cane for gait stability (though patient may initially refuse due to stigma; discuss benefits and independence). **Psychosocial Support:** - **Depression screening and management**: Depression affects 50% of PD patients and worsens outcomes; screen regularly using validated scale (GDS, PHQ-9). Refer for counseling or antidepressant if indicated. - **Caregiver support**: Parkinson's disease places significant burden on family caregivers; offer support groups, respite care, information resources, and education on disease progression and care strategies. - **Communication**: For dysarthric patients, allow extra time for speech; speak slowly and clearly when addressing patient; use written communication if helpful; consider speech therapy referral. - **Cognitive assessment**: Monitor for MCI or dementia; refer for neuropsychological testing if concerned. - **Sexuality and intimacy**: Erectile dysfunction and reduced sexual desire common; discuss openly; offer education and treatment options. **Driving Safety:** - Counsel patient and family regarding driving restrictions based on disease severity, reaction time, postural stability, and medication status (especially daytime somnolence with dopamine agonists). - In Philippines, regulations vary; generally, patients with active motor symptoms affecting safety should not drive; encourage discussion with neurologist and licensing authority. - Arrange driving assessment (occupational therapy) if patient insists on continuing to drive; formal testing provides objective data. **Medication Management in the Philippines:** - Access to dopaminergic medications varies by region and healthcare system (public vs. private). In rural areas and some government facilities, medications may be limited or generic only. - Work with patient and physician to explore: - Government assistance programs (DOH, PhilHealth for certain medications). - Hospital pharmacy discounts or generic alternatives (carbidopa-levodopa, bromocriptine, ropinirole generics available in Philippines). - NGO support organizations. - Medications that can be managed initially (e.g., starting with dopamine agonist monotherapy if available, though less effective than levodopa; adding levodopa later when symptoms progress). - Document patient's access barriers and advocate for affordable care. **Community Resources (Philippines Context):** - Neurology clinics at major tertiary centers (UP-PGH, Philippine Heart Center, National Stroke Foundation Centers). - Support groups and patient advocacy organizations (though limited availability). - Physical therapy and occupational therapy services (often private; limited in rural areas). - Home health nursing if available; elder care agencies for in-home support. **Teaching for Family Caregivers:** - Disease progression: Early disease is mildly disabling; middle disease involves medication complications and significant functional loss; advanced disease requires 24-hour care. - Medication administration: On-time dosing is critical; set up system (calendar, alarms) to ensure compliance. - Safety measures: Fall prevention, swallowing precautions, constipation management, recognition of medication side effects. - When to seek help: Sudden worsening (may indicate infection, medication change, or other acute illness), severe dyskinesias, psychotic symptoms, falls with injury, suicidal ideation. - Self-care: Caregivers must maintain their own health; encourage respite care, support groups, and professional counseling if caregiver burden is high. **Documentation and Monitoring:** - **Initial assessment**: Motor symptoms (tremor, rigidity, bradykinesia, postural instability), nonmotor symptoms (depression, cognitive status, autonomic symptoms), functional level (ADL independence), medications and dosing schedule, comorbidities. - **Ongoing monitoring**: Motor symptom severity and fluctuations (on-off pattern, dyskinesias, freezing), side effects, ADL performance, medication adherence, fall history, nutrition and weight, mood and cognition. - **Periodic reassessment**: Unified Parkinson's Disease Rating Scale (UPDRS) or Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) at regular intervals (typically annually or more often if disease advanced); assessment of need for medication adjustment or specialist referral.